ClinicalTrials.gg
CompletedNCT00385658Updated Feb 24, 2017

Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome

A Phase 4 interventional study of Fluvastatin extended release, fenofibrate and Fixed combination simvastatin/ezetimibe in Dyslipidemia, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies in Dyslipidemias by Novartis — 5 open to participants now, 10 under way, 5 of them phase 3. Dyslipidemias · Novartis.

Enrollment
19th of 22
75 · median 216
Started
2006
the only one that year
Phase 4
10 of 27
1 open now
Registered
7th of 27
by date

Among the 27 studies in Dyslipidemias by Novartis, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2006, is one of 10 in phase 4, and was the 7th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

5 of the 27 studies in Dyslipidemias by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Dyslipidemias by Novartis, or all of them as a file.
02

Study summary

This study will investigate the effects of the combination of fluvastatin and fenofibrate on dyslipidemia in comparison to the combination of simvastatin and ezetimibe.

03

Conditions studied

  • Dyslipidemia

Keywords

  • Dyslipidemia
  • metabolic syndrome
  • fluvastatin
  • fenofibrate
  • simvastatin
  • ezetimibe
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written to participate in the study prior to any study procedures.
  • Male or female subjects, age between 18-75 years inclusive.
  • All women of child bearing potential must have a negative pregnancy test
  • Metabolic Syndrome according to the International Diabetes Federation definition:

    • Low plasma HDL-C (Men \< 40 mg/dl ; Women \< 50 mg/dl ).
    • Elevated waist circumference (men ≥ 94 cm, women ≥ 80cm)
    • And one or more of the following criteria:

      • Triglycerides ≥ 150 mg/d.l
      • Raised blood pressure (DBP ≥ 85 mmHg and/or SBP ≥ 130mmHg ) or treated hypertension.
      • Fasting plasma glucose≥ 100mg/dl.
      • Previously diagnosed type 2 diabetes.

Exclusion criteria

Exclusion Criteria:

  • Dyslipidemia secondary to other causes such as nephrotic syndrome, disease.
  • Type 1 diabetes.
  • > 9.5%.
  • Unexplained serum creatine phosphokinase > 2 x .
  • History of myocardial infarction and/or cerebral stroke and/or unstable angina pectoris.
  • Known or suspected and warnings according to the country specific label for the drugs.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Interventions

  • DrugFluvastatin extended release, fenofibrate

    Drug pages: Fluvastatin · Fenofibrate

  • DrugFixed combination simvastatin/ezetimibe
06

What researchers measure

Primary outcomes

  1. High density lipoprotein cholesterol (HDL-C) measured at the end of each study period.

Secondary outcomes

  1. Compared at the end of each treatment period:

  2. patients reaching target levels of low density lipoprotein cholesterol (LDL-C) <100mg/dl

  3. patients reaching target levels of non-HDL-C <130mg/

  4. LDL-C/HDL-C

  5. Triglycerides

  6. LDL subfractions in a subgroup of patients

07

Study locations

2 sites
  • Investigative Centers, Germany
  • Novartis Pharma AG
    Basel, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2006
First posted
Oct 11, 2006
Start
Aug 2006
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00385658
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Oct 11, 2006
Start date
Aug 2006
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Feb 24, 2017

Study contacts

Novartis Pharma AG
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion